| pubmed-article:18434751 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0011881 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0034787 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0162574 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0288171 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:18434751 | lifeskim:mentions | umls-concept:C0070317 | lld:lifeskim |
| pubmed-article:18434751 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18434751 | pubmed:dateCreated | 2008-5-16 | lld:pubmed |
| pubmed-article:18434751 | pubmed:abstractText | The aim of this post-hoc analysis of a prospective study in patients with type 2 diabetic nephropathy was to investigate whether treatment with the angiotensin II type 1 receptor blocker irbesartan leads to a reduction in the serum levels of the advanced glycation end products (AGEs) pentosidine and N(epsilon)-carboxymethyllysine (CML). | lld:pubmed |
| pubmed-article:18434751 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18434751 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18434751 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18434751 | pubmed:issn | 1660-2110 | lld:pubmed |
| pubmed-article:18434751 | pubmed:author | pubmed-author:Collaborative... | lld:pubmed |
| pubmed-article:18434751 | pubmed:author | pubmed-author:WolfGunterG | lld:pubmed |
| pubmed-article:18434751 | pubmed:author | pubmed-author:SteinGünterG | lld:pubmed |
| pubmed-article:18434751 | pubmed:author | pubmed-author:FrankeSybille... | lld:pubmed |
| pubmed-article:18434751 | pubmed:author | pubmed-author:BuschMartinM | lld:pubmed |
| pubmed-article:18434751 | pubmed:author | pubmed-author:RohdeRichard... | lld:pubmed |
| pubmed-article:18434751 | pubmed:copyrightInfo | Copyright 2008 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:18434751 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18434751 | pubmed:volume | 108 | lld:pubmed |
| pubmed-article:18434751 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18434751 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18434751 | pubmed:pagination | c291-7 | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:meshHeading | pubmed-meshheading:18434751... | lld:pubmed |
| pubmed-article:18434751 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18434751 | pubmed:articleTitle | Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. | lld:pubmed |
| pubmed-article:18434751 | pubmed:affiliation | Department of Internal Medicine III, University of Jena, Jena, Germany. martin.busch@med.uni-jena.de | lld:pubmed |
| pubmed-article:18434751 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18434751 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
